AELMHU updates, with a new four-monthly report, the annual data on access to orphan drugs in Spain. Its objective is to be able to measure the evolution of access to this type of treatment in our country, providing new data every four months. The information is presented in aggregate form and updated to April 30, 2023, and only includes products with current orphan designation.
In the European Union, 146 orphan treatments have marketing authorization, of which 127 have already reached Spain. Of these 127, 70 are currently financed by the National Health System (SNS).
The average waiting time from when orphan drugs obtain National Code until they are incorporated into the SNS is 26 months.
As of today, 57 orphan drugs are not included in the SNS, including the 29 products that already have a negative financing resolution.
You can learn more about the report in this infographic here and the summary of the data.